PhRMA Asks Federal Court to Strike Down Arkansas’ Novel 340B Nondiscrimination Law

PhRMA yesterday asked a federal district court to strike down Arkansas' 340B nondiscrimination law, Act 1103.

Pharmaceutical Research and Manufacturers of America (PhRMA) asked a federal district court yesterday to rule that Arkansas’s 340B nondiscrimination act does not require drug manufacturers “to offer price discounts under the 340B program to contract pharmacies in Arkansas.”

Read More »

340B Dispute Resolution Process is Constitutional, Feds Tell Court

A recent U.S. Supreme Court ruling confirms that the 340B administrative dispute resolution process is constitutional, government lawyers told a federal district judge this month.

A recent U.S. Supreme Court ruling about administrative law judges who hear patent disputes confirms that rules establishing the 340B program’s administrative dispute resolution (ADR) process are constitutional, government lawyers told a federal district judge this month.

Read More »

Hospital Groups and Drug Industry Vendor File Briefs in Sanofi’s 340B Contract Pharmacy Suit

A federal district judge this week let six hospitals groups and a drug industry vendor file amicus briefs in Sanofi's 340B contract pharmacy lawsuit.

A federal district judge this week gave six hospital groups and a drug industry services provider permission to separately offer their expert advice in drug manufacturer Sanofi’s 340B contract pharmacy lawsuit.

Please Login or Become a

Read More »

Rough Sailing for Drug Pricing Reform in Congress

Congressional Democrats continue to wrangle over a $3.5 trillion economic and social welfare bill that is expected to include major drug pricing reforms.

It appears increasingly likely that congressional Democrats will miss their self-appointed deadline to pass and sent to President Biden this week a $3.5 trillion economic and social welfare bill including major drug pricing reforms.

Please Login

Read More »

GOP Senator Files Bill to Preserve Trump’s 340B Insulin/EpiPen Mandate

Sen. John Kennedy (R-La.) has introduced legislation to preserve the Trump administration’s controversial requirement that community health centers pass along all their 340B savings on insulin and EpiPen-like devices to low-income, uninsured, and/or underinsured patients.

A Republican U.S. senator on an important health care spending committee wants Congress to pass a law preserving the Trump administration’s controversial requirement that community health centers pass along all their 340B savings on insulin and EpiPen-like devices to low-income,

Read More »

Hospitals Ask Hill Leaders to Shield 340B, as Vote Nears on Drug Pricing Reform

Hospital groups urged congressional leaders in a Sept. 24 letter to exclude language “that would negatively impact 340B” from major drug pricing reforms that could be voted on this week.

Six national hospital groups late last week urged Democratic and Republican congressional leaders to exclude language “that would negatively impact 340B” from major drug pricing reforms that could be voted on this week.

Please Login or

Read More »

Janssen Providing Refunds for 340B Overcharges Including Diabetes Drug

Janssen Pharmaceuticals is providing refunds for 340B overcharges on 14 widely used products during the first and second quarters of 2021.

Drug manufacturer Janssen, a Johnson & Johnson company, has notified 340B covered entities they are or might be owed refunds for overcharges on 14 widely used products during the first and second quarters of 2021.

Please

Read More »

Seven-Term Senator Grassley, Often Attuned to 340B, Will Run Again in 2022

Sen. Chuck Grassley (R-Iowa), one of the most-engaged members of Congress on 340B matters, is seeking an eighth Senate term.

U.S. Sen. Chuck Grassley (R-Iowa)—one of the most-engaged members of Congress on 340B matters—has announced he will seek an eighth Senate term in next year’s congressional elections.

Please Login or Become a Paid Subscriber to View

Read More »

Judge Rejects Novartis’ Request to Speed Up Hearing in 340B Contract Pharmacy Lawsuit

A federal judge yesterday denied drug maker Novartis’ request to speed up a hearing on its request that the judge block the government from punishing the company over its denials of 340B pricing when health care providers use contract pharmacies

A federal judge yesterday denied drug maker Novartis’ request to speed up a hearing on its request that the judge block the government from punishing the company over its denials of 340B pricing when health care providers use contract pharmacies.

Read More »

News Alert: New Senate Bill Would Let HRSA Audit 340B Providers to See How They Use 340B Net Income

Senator Mike Braun (R-IN) has introduced legislation to let the government audit 340B entities to determine how they use net income from 340B savings.

U.S. Sen. Mike Braun (R-Ind.) introduced legislation last night to let the federal government audit 340B covered entities to determine how they use net income from drugs bought under the 340B program.

Please Login or Become

Read More »
Generic selectors
Exact matches only
Search in title
Search in content